Research Analysts Offer Predictions for PTGX Q1 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Protagonist Therapeutics in a research report issued on Monday, August 31st. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.88) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $170.00 target price on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $4.22 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q2 2027 earnings at ($0.89) EPS, Q3 2027 earnings at ($0.88) EPS and Q4 2027 earnings at ($0.15) EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The firm had revenue of $213.47 million during the quarter, compared to the consensus estimate of $212.03 million. The firm’s revenue was up 3746.8% compared to the same quarter last year.

PTGX has been the subject of a number of other research reports. Barclays increased their price objective on shares of Protagonist Therapeutics from $153.00 to $180.00 and gave the stock an “overweight” rating in a research report on Tuesday. Citizens Jmp boosted their target price on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Citigroup upped their price target on Protagonist Therapeutics from $175.00 to $182.00 and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen upgraded Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 22nd. Finally, Wolfe Research reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research note on Monday. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $147.13.

Protagonist Therapeutics Price Performance

Shares of PTGX opened at $146.49 on Wednesday. Protagonist Therapeutics has a 1-year low of $54.50 and a 1-year high of $160.81. The stock has a market cap of $9.48 billion, a PE ratio of 142.22 and a beta of 1.78. The firm has a 50-day simple moving average of $139.71 and a two-hundred day simple moving average of $113.59.

Insider Buying and Selling

In related news, Director William D. Waddill sold 9,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director directly owned 7,825 shares of the company’s stock, valued at $922,880.50. This represents a 53.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 65,761 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $149.11, for a total transaction of $9,805,622.71. Following the sale, the chief executive officer owned 523,478 shares in the company, valued at approximately $78,055,804.58. This trade represents a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 118,000 shares of company stock valued at $16,921,379 in the last 90 days. Company insiders own 5.19% of the company’s stock.

Institutional Trading of Protagonist Therapeutics

Several hedge funds have recently modified their holdings of PTGX. BlackRock Inc. purchased a new position in Protagonist Therapeutics in the second quarter valued at $1,263,535,000. California State Teachers Retirement System increased its holdings in Protagonist Therapeutics by 12,217.3% during the 2nd quarter. California State Teachers Retirement System now owns 7,227,439 shares of the company’s stock worth $885,939,000 after purchasing an additional 7,168,762 shares during the period. Johnson & Johnson purchased a new stake in Protagonist Therapeutics during the 2nd quarter worth about $300,220,852. Jupiter Topco LLC acquired a new stake in Protagonist Therapeutics in the 2nd quarter valued at about $261,039,000. Finally, Janus Henderson Group PLC raised its position in Protagonist Therapeutics by 140.7% in the 4th quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock valued at $231,355,000 after purchasing an additional 1,549,160 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics News Roundup

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Higher analyst price target: BMO Capital Markets raised its target for PTGX from $178 to $190 and maintained an “outperform” rating, implying approximately 29.7% upside from the referenced share price. The increase reflects greater confidence in MIMRYLO and Protagonist’s broader growth prospects.
• Positive Sentiment: MIMRYLO gains commercial potential: The FDA approval gives Protagonist an important marketed therapy for polycythemia vera, potentially creating a new revenue stream and strengthening the company’s position in hematology. Truist said the product could have meaningful commercial potential after approval. Protagonist Therapeutics’ MIMRYLO Holds Commercial Potential After FDA Approval
• Positive Sentiment: Pipeline and partner milestones remain catalysts: Wedbush views Protagonist’s proprietary pipeline as the main long-term growth driver, while additional Takeda milestones could further validate the company’s platform and provide potential payments or royalties. Protagonist Therapeutics’ Own Pipeline Seen as Main Long-Term Growth Driver
• Neutral Sentiment: Valuation and execution matter: With PTGX trading near its 12-month high and carrying a high price-to-earnings multiple, investors may demand strong MIMRYLO uptake, successful commercialization, and continued pipeline progress. The FDA decision is favorable, but sales execution and future clinical or regulatory milestones remain important.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.